The SEAD™GLOBAL ENDOMETRIAL ABLATION MARKET GAME CHANGER

OCON’S SEAD™ - currently in Phase II Clinical Studies - offers disposable, point of care therapy for abnormal uterine bleeding – a far more comfortable and cost effective alternative for hundreds of thousands of women per year who opt for the current procedure.

The Problem - Abnormal Uterine Bleeding (AUB)

Global endometrial ablation (GEA) is a second line of treatment (Post hormonal treatment) which requires hospitalization and general anesthesia and is very painful.

The Solution - The SEAD™

The SEAD™ is an acute intrauterine product for women with abnormal uterine bleeding, a problem affecting 1 of 5 women globally. The current standard of care (global ablation) is considered invasive, burdensome, debilitating and costly. 

Second generation ablation technologies currently in use require capital equipment, extensive training, general anesthesia & hospitalization and cause high indirect cost of annually $12B in the US alone.

The SEAD™ is a market game changer through simplicity, cost effectiveness and new and innovative yet gentle “substance-derived ablation” technology.

The SEAD™ value proposition:

  • Highly cost effective: <1/2 compared to current treatments.
  • Less invasive for women: no need for hospitalization or general anesthesia
  • A 30 minute in-office procedure: as easy, quick and painless as an IUD insertion.
  • Short learning curve compared to current options.
  • Overcomes problems of uterine size and/or shape limitations.

The SEAD™ Endometrial Ablation is self-limiting (stops Ablation at Basal Layer) and may offer an Endometrial ‘reset’ (vs. destruction) as done today. Phase I Clinical Studies have demonstrated safety. Phase II Clinical Studies are currently ongoing.

The SEAD™ has the potential of becoming a strong and attractive player in the worldwide GEA markets through its simplicity, cost effectiveness and new and innovative yet gentle “substance-based Ablation” technology.


* Parker P.M. ICON Group International, Inc.; Las Vegas, NV: 2017. The 2018-23 World Outlook for Endometrial Ablation Devices.

 

 

IUB, OCON and the OCON and IUB logos are trademarks of OCON Medical Ltd.
Ballerine and Sphera are registered trademarks of OCON Medical Ltd.
OCON products are not yet approved for sale in the United States.
IUB Ballerine MAXI: CE mark pending. Copyright OCON Medical Ltd., d/b/a OCON Healthcare.